Gemzar
Company: Eli Lilly
Approval Status: Approved August 1998
Treatment for: Lung cancer
Areas: Oncology
Possible similar drugs: Gemzar
| General Information | Side Effects |
General Information
Gemzar is indicated in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer. It is also indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemzar is indicated for patients previously treated with 5-FU.
Side Effects
Prolongation of the infusion time beyond 60 minutes and more frequent than weekly doses have been shown to increase toxicity. Gemzar can surpress bone marrow function as manifested by leukopenia, thrombocytopenia and anemia. Patients should also be monitores for myelosurpression during therapy. Gemzar can also cause fetal harm when administered to a pregnant woman.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
